Broad spectrum of activity, favorable safety profiles, and multiple indications favored fluoroquinolone use as a widely prescribed class of antimicrobials in the 1990s and early 2000s \[[@CIT0001]\]. However, continued use of fluoroquinolones is associated with development of resistance \[[@CIT0002]\]. Introduction of the first quinolone, nalidixic acid, rapidly led to the development of resistance, especially in Escherichia *coli* \[[@CIT0002], [@CIT0003]\]. Resistance mutations were genetically mapped to subunits of deoxyribonucleic acid (DNA) gyrase, which were found to be the target of fluoroquinolone antibiotics \[[@CIT0004]\].

C*lostridioides difficile*, a Gram-positive, anaerobic, spore-forming bacterium, is also associated with fluoroquinolone resistance. The epidemic caused by the ribotype 027 strain was primarily characterized by the acquisition of a transposable element and a mutation in the *gyrA* gene that ultimately led to high-level fluoroquinolone resistance within ribotype 027 *C difficile* strains \[[@CIT0005]\]. Distinct mutation acquisition events led to the generation of 2 unique fluoroquinolone-resistant lineages designated FQR1 and FQR2 \[[@CIT0006]\]. Both lineages emerged with high probability in the United States in the early 1990s. However, the use of whole genome sequencing to assess national and global dissemination have been limited by a low number of ribotype 027 isolates available for investigation \[[@CIT0005]\]. In addition, previous reports are limited by the lack of United States-derived ribotype 027 *C difficile* strains, especially of the FQR1 lineage.

Considering this, we sought to conduct a large, epidemiologic study to better understand the emergence and dissemination of ribotype 027 in the United States. Since 2011, we have conducted several Texas state-wide surveillance studies to type *C difficile* isolates obtained from hospitalized patients with a focus on healthcare centers in Houston, the fourth largest city in the United States \[[@CIT0007], [@CIT0008]\]. *Clostridioides difficile* ribotype 027 comprised approximately 20% of isolates obtained from these studies. Given the international healthcare nature of Houston, which includes the Texas Medical Center---the largest medical center in the world---we investigated whether both ribotype 027 lineages are present, providing a unique opportunity to study the evolution of this epidemic strain in the United States.

METHODS {#s1}
=======

Sample Collection {#s2}
-----------------

Institutional Review Boards at the University of Houston and participating hospitals approved this study. Fecal samples were collected from hospitalized patients diagnosed with *C difficile* infection (CDI) between 2011 and 2018. All patient samples were deidentified. Isolates were purified and ribotyped as previously described \[[@CIT0007]\]. Previously sequenced *C difficile* strains from He et al \[[@CIT0005]\] and Steglich et al \[[@CIT0010]\] were used for comparative bioinformatics analyses.

Sequencing and Analyses {#s3}
-----------------------

Deoxyribonucleic acid was extracted using either the QIAamp DNA mini kit (QIAGEN) or AnaPrep automated DNA extractor (BioChain). Deoxyribonucleic acid was quantified by NanoDrop (ThermoFisher Scientific) and Qubit (ThermoFisher Scientific), and DNA quality was assessed using a BioAnalyzer (Agilent). The DNA libraries were prepared according to Illumina's protocols, multiplexed on a flow cell, and run on a NextSeq (Illumina) using paired-end sequencing. The generated fastq files were trimmed using Trimmomatic \[[@CIT0011]\] and sequencing quality was examined by software FastQC. The presence of known antimicrobial resistance genes was determined from cleaned reads using the ARG-ANNOT database \[[@CIT0012]\] and SRST2 pipeline \[[@CIT0013]\].

For whole genome SNP analysis, cleaned sequence reads were mapped to the R20291 reference genome (GenBank accession number [FN545816](FN545816)) using the RedDog pipeline according to the developer's guidelines (<https://github>. com/katholt/RedDog). In brief, Bowtie2 version 2.2.3 was used for mapping \[[@CIT0014]\] and SAMtools version 0.1.19 was used for calling SNPs \[[@CIT0015]\]. Only high-quality SNPs were used for phylogenetic analyses \[[@CIT0005], [@CIT0010], [@CIT0016]\]. Phylogenetic trees were created in FigTree and heat maps were generated using R. STRING (version 9.05) was used for pathway analyses. BEAST 2.4.7 was used to incorporate spatial and temporal variables into the phylogeny \[[@CIT0020]\]. Analyses were done after the tutorial "Ancestral reconstruction/discrete phylogeography" with BEAST 2.0 (available at <http://www.beast2.org/> wiki/index.php/Tutorials) and by using previously published manuscripts as guides \[[@CIT0010]\]. Phylogeographic reconstruction was done using SpreaD3 \[[@CIT0021]\]. Quark (<https://zhanglab.ccmb.med.umich.edu/QUARK/>) was used for modeling SNP effects on protein structure \[[@CIT0022]\].

RESULTS {#s4}
=======

Whole genome sequencing data from a total of 108 ribotype 027 (NAP1/BI) *C difficile* isolates were analyzed from 23 different geographic regions worldwide. Among the 108 samples, 83 (77%) were isolated from the United States, 76 of which were collected from 15 different regional hospitals in Texas ([Table 1](#T1){ref-type="table"}), primarily from the greater Houston metropolitan area. After mapping to the R20291 reference genome, SNP calling identified 2841 high-quality discriminatory SNPs, which defined the maximum-likelihood phylogeny ([Figure 1A](#F1){ref-type="fig"}). The SNPs consisted of 900 nonsynonymous mutations, 1404 synonymous substitutions, and 537 intergenic changes. Two disparate groupings of isolates affected the resolution of the phylogeny; however, the FQR lineages were prominent after removing these outlier groups ([Figure 1B](#F1){ref-type="fig"}). One group of outliers was identified as of pre-epidemic origin ([Figure 1A](#F1){ref-type="fig"}, green), whereas the other grouping ([Figure 1A](#F1){ref-type="fig"}, blue) clustered amongst other FQR1 strains. Upon further examination of these distant FQR1 strains, we identified 760 SNP sites, \>500 indels, and significant homologous recombination that was shared amongst these 2 distant FQR1 isolates compared with other FQR1 strains ([Supplemental Figure 1A](#sup1){ref-type="supplementary-material"}). These changes were highly related and corresponded to shared changes in metabolic pathways ([Supplemental Figure 1B](#sup1){ref-type="supplementary-material"}). In total, the phylogenetic tree ([Figure 1B](#F1){ref-type="fig"}) consists of 49 FQR1 strains (n = 35 Texas-specific), 54 FQR2 strains (n = 36 Texas-specific), and 5 pre-epidemic strains. To our knowledge, this is the largest collection of FQR1 strains that has been analyzed thus far and, overall, the largest collection of ribotype 027 strains that has been sequenced from the United States. It is interesting to note that the maximum-likelihood phylogeny tended to closely group the Texas strains within each lineage resulting in a sublineage, which suggests that there is a local genetic uniqueness to these strains.

###### 

Strain Information

  Isolate    Isolation Country   Isolation Region   FQR Lineage    Reference
  ---------- ------------------- ------------------ -------------- -------------------------------
  07-00080   Germany             Stuttgart          FQR2           Steglich et al \[[@CIT0010]\]
  08-00070   Germany             Landau/Pfalz       FQR2           Steglich et al \[[@CIT0010]\]
  09-00022   Germany             Bad Langensalza    FQR2           Steglich et al \[[@CIT0010]\]
  09-00077   Germany             Sindelfingen       FQR2           Steglich et al \[[@CIT0010]\]
  10-00484   Germany             Leipzig            FQR1           Steglich et al \[[@CIT0010]\]
  12-00001   Germany             Homburg            FQR2           Steglich et al \[[@CIT0010]\]
  12-00004   Germany             Bielefeld          FQR2           Steglich et al \[[@CIT0010]\]
  12-00014   Germany             Leipzig            FQR1           Steglich et al \[[@CIT0010]\]
  12-00017   Germany             Bad Berka          FQR1           Steglich et al \[[@CIT0010]\]
  12-00018   Germany             Radebeul           FQR1           Steglich et al \[[@CIT0010]\]
  12-00019   Germany             Zittau             FQR1           Steglich et al \[[@CIT0010]\]
  Aus001     Australia           Melbourne          FQR2           He et al \[[@CIT0005]\]
  Aus005     Australia           Melbourne          FQR2           He et al \[[@CIT0005]\]
  Bir002     United Kingdom      Birmingham         FQR2           He et al \[[@CIT0005]\]
  BMC-18     United States       Texas              FQR1           From this study
  Can010     Canada              Montreal           FQR2           He et al \[[@CIT0005]\]
  Exe014     United Kingdom      Exeter             FQR2           He et al \[[@CIT0005]\]
  Exe015     United Kingdom      Exeter             FQR2           He et al \[[@CIT0005]\]
  FCH-1      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  FCH-2      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  FCH-4      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  Ham005     United Kingdom      London             FQR2           He et al \[[@CIT0005]\]
  Kor002     Korea               Korea              FQR1           He et al \[[@CIT0005]\]
  Kor003     Korea               Korea              FQR1           He et al \[[@CIT0005]\]
  Kor004     Korea               Korea              FQR1           He et al \[[@CIT0005]\]
  Kor005     Korea               Korea              FQR1           He et al \[[@CIT0005]\]
  LSTM002    United States       Pennsylvania       FQR1           He et al \[[@CIT0005]\]
  LSTM005    United States       Arizona            FQR1           He et al \[[@CIT0005]\]
  LSTM006    United States       Arizona            FQR1           He et al \[[@CIT0005]\]
  LSTM022    United States       Oregon             FQR1           He et al \[[@CIT0005]\]
  LSTM025    United Kingdom      Dundee             FQR2           He et al \[[@CIT0005]\]
  LTC10      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC-14     United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC15      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC15A     United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC15B     United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC19      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC-36     United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC39      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC39A     United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC44      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC5A      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  LTC7B      United States       Texas              FQR2           Endres et al \[[@CIT0009]\]
  MCD-116    United States       Texas              FQR1           From this study
  MCD-173    United States       Texas              FQR1           From this study
  MCD-60     United States       Texas              FQR1           From this study
  MDA133     United States       Texas              FQR2           From this study
  MHS-301    United States       Texas              FQR2           From this study
  MHS-322    United States       Texas              Pre-epidemic   From this study
  MHS-479    United States       Texas              FQR2           From this study
  MHS-480    United States       Texas              FQR2           From this study
  MHS490     United States       Texas              Pre-epidemic   From this study
  MT1039     United States       Texas              FQR1           From this study
  MT1300     United States       Texas              FQR2           From this study
  MT1344     United States       Texas              FQR2           From this study
  MT1349     United States       Texas              FQR1           From this study
  MT1410     United States       Texas              FQR2           From this study
  MT1433     United States       Texas              FQR2           From this study
  MT1443     United States       Texas              FQR2           From this study
  MT1453     United States       Texas              FQR2           From this study
  MT1470     United States       Texas              FQR2           From this study
  MT1641     United States       Texas              FQR2           From this study
  MT1753     United States       Texas              FQR1           From this study
  MT1821     United States       Texas              FQR1           From this study
  MT188      United States       Texas              FQR1           From this study
  MT189      United States       Texas              FQR2           From this study
  MT201      United States       Texas              FQR1           From this study
  MT2040     United States       Texas              FQR1           From this study
  MT207      United States       Texas              FQR1           From this study
  MT2252     United States       Texas              FQR1           From this study
  MT2626     United States       Texas              FQR1           From this study
  MT2710     United States       Texas              FQR1           From this study
  MT2715     United States       Texas              FQR2           From this study
  MT2780     United States       Texas              FQR1           From this study
  MT2795     United States       Texas              FQR2           From this study
  MT3133     United States       Texas              FQR1           From this study
  MT3227     United States       Texas              FQR2           From this study
  MT3678     United States       Texas              FQR1           From this study
  MT443      United States       Texas              FQR1           From this study
  MT-4447    United States       Texas              FQR1           From this study
  MT-5025    United States       Texas              FQR1           From this study
  MT-5051    United States       Texas              FQR2           From this study
  MT-5055    United States       Texas              FQR1           From this study
  MT-5064    United States       Texas              FQR1           From this study
  MT5314     United States       Texas              FQR1           From this study
  MT5337     United States       Texas              FQR1           From this study
  MT5342     United States       Texas              FQR2           From this study
  MT5370     United States       Texas              FQR1           From this study
  MT785      United States       Texas              FQR1           From this study
  P23        United States       Pennsylvania       FQR2           He et al \[[@CIT0005]\]
  P31        United States       Pennsylvania       FQR2           He et al \[[@CIT0005]\]
  P45        United States       Pennsylvania       FQR2           He et al \[[@CIT0005]\]
  R20291     United Kingdom      Stoke Mandeville   FQR2           He et al \[[@CIT0005]\]
  SH1171     United States       Texas              FQR1           From this study
  SH515      United States       Texas              FQR1           From this study
  SH541      United States       Texas              FQR2           From this study
  SH-769     United States       Texas              FQR1           From this study
  SH-797     United States       Texas              FQR2           From this study
  SH-804     United States       Texas              FQR1           From this study
  VM-2-S41   United States       Texas              FQR1           From this study
  VM-2-S60   United States       Texas              FQR1           From this study
  VM-5-S43   United States       Texas              FQR1           From this study
  VM-5-S59   United States       Texas              FQR1           From this study
  VM-8-S42   United States       Texas              FQR1           From this study
  VM-8-S58   United States       Texas              FQR1           From this study
  WH-28      United States       Texas              FQR1           From this study
  WH-29      United States       Texas              FQR2           From this study
  ZKS-32     United States       Kansas             FQR1           From this study

![Maximum-likelihood phylogeny based on 2841 core genome single-nucleotide polymorphisms amongst ribotype 027 *Clostridioides difficile* samples. (A) The phylogenetic tree includes 108 samples, which depicts some isolates as outliers. (B) A zoomed in phylogenetic tree clearly separates the FQR1 and FQR2 lineages.](ofidis_ofz013_f0001){#F1}

The major SNP difference that delineates the pre-epidemic strain from the epidemic strains is the *gyrA* mutation (c.245C\>T) at position 6310 (R20291 genome location), which confers high-level fluoroquinolone resistance in the FQR1 and FQR2 lineages. The primary SNP differences between the FQR1 and FQR2 could be titrated to 28 SNP differences ([Table 2](#T2){ref-type="table"}), 21 of which are nonsynonymous and unique compared with the SNPs identified by He et al \[[@CIT0005]\]. Of the 21 nonsynonymous SNP differences, 8 SNPs were located to genes linked to drug resistance in orthologous species, including the DNA-directed ribonucleic acid polymerase beta chain (encodes rifampicin resistance), putative penicillin-binding proteins, a putative 5-nitroimidazole reductase, and a putative drug/sodium antiporter \[[@CIT0023]\]. Using predictive protein modeling, the SNP in putative 5-nitroimidazole reductase within FQR1 strains affects protein folding and may impact nitroimidazole (metronidazole) action ([Supplemental Figure 2](#sup2){ref-type="supplementary-material"}). Other SNPs identified occurred more frequently in FQR1 strains and were found in genes involved in cell metabolism, which suggests that this lineage's worldwide dissemination may have been hampered by cell fitness.

###### 

Prominent SNP Differences Between FQR1 and FQR2 Strains

  Position (bp)   Gene            Gene Product                                                                                                 Change          R20291   FQR1   FQR2
  --------------- --------------- ------------------------------------------------------------------------------------------------------------ --------------- -------- ------ ------
  95422           CDR20291_0060   DNA-directed RNA polymerase beta chain                                                                       Nonsynonymous   G        A      G
  95552           CDR20291_0060   DNA-directed RNA polymerase beta chain                                                                       Nonsynonymous   A        G      A
  118571          CDR20291_0090   Putative ribosomal protein                                                                                   Nonsynonymous   G        A      G
  563962          CDR20291_0466   Chemotaxis protein methyltransferase                                                                         Nonsynonymous   A        C      A
  879963          CDR20291_0712   Penicillin-binding protein                                                                                   Nonsynonymous   C        T      C
  1026853         CDR20291_0842   2-isopropylmalate synthase                                                                                   Synonymous      G        A      G
  1202866         CDR20291_0985   Putative penicillin-binding protein                                                                          Nonsynonymous   C        G      C
  1203554         CDR20291_0985   Putative penicillin-binding protein                                                                          Nonsynonymous   C        T      C
  1232712         CDR20291_1013   Conserved hypothetical protein                                                                               Nonsynonymous   C        A      C
  1460490         CDR20291_1231   Probable transporter                                                                                         Nonsynonymous   A        C      A
  1547479         CDR20291_1308   Putative 5-nitroimidazole reductase                                                                          Nonsynonymous   T        A      T
  1600434         CDR20291_1354   Putative drug/sodium antiporters                                                                             Nonsynonymous   G        C      G
  1600436         CDR20291_1354   Putative drug/sodium antiporters                                                                             Nonsynonymous   T        C      T
  1794733         CDR20291_1522   2-component response regulator                                                                               Nonsynonymous   A        G      A
  2448413         CDR20291_2088   ATP-dependent RNA helicase                                                                                   Nonsynonymous   A        G      A
  2459187         CDR20291_2096   Cyclomaltodextrinase (maltogenic alpha-amylase)                                                              Synonymous      A        G      A
  2568546                                                                                                                                      Intergenic      G        A      G
  2649551         CDR20291_2259   Quinolinate synthetase A                                                                                     Nonsynonymous   G        T      G
  2665592         CDR20291_2272   Putative signaling protein                                                                                   Nonsynonymous   T        G      T
  2803020         CDR20291_2394   Putative histidinol-phosphate aminotransferase                                                               Nonsynonymous   G        A      G
  2931889         CDR20291_2499   Hypothetical protein                                                                                         Nonsynonymous   A        G      A
  2942446                                                                                                                                      Intergenic      G        A      G
  3111866         CDR20291_2643   Phosphoenolpyruvate-protein phosphotransferase                                                               Synonymous      C        A      C
  3128507         CDR20291_2657   Capsular polysaccharide biosynthesis protein                                                                 Synonymous      A        G      A
  3163982         CDR20291_2682   Cell surface protein (S-layer precursor protein)                                                             Nonsynonymous   G        A      G
  3248655         CDR20291_2744   [d]{.smallcaps}-alanine--poly(phosphoribitol) ligase subunit 1 ([d]{.smallcaps}-alanine-activating enzyme)   Nonsynonymous   A        C      A
  3500659                                                                                                                                      Intergenic      G        A      G
  3600925         CDR20291_3018   Ribonuclease R                                                                                               Nonsynonymous   G        T      G

Abbreviations: bp, base pair; DNA, deoxyribonucleic acid; RNA, ribonucleic acid; SNP, single-nucleotide polymorphism.

Gene presence or absence was also used to discriminate ribotype 027 strains \[[@CIT0005]\]. This analysis separated strains into distinct groups, possibly due to differences in sequence coverage in some strains ([Figure 2A](#F2){ref-type="fig"}). However, targeted analysis of high variability regions separated strains into 2 prominent groups, corresponding to FQR1 and FQR2 lineages ([Figure 2A](#F2){ref-type="fig"}). The region shared among epidemic strains (FQR1 and FQR2) that was absent in the pre-epidemic strain was the transposable element, *Tn6192*. In contrast, *Tn6105* was present in FQR2 strains and was absent in FQR1 strains. The presence or absence of a genomic region corresponding to ABC transporter proteins was not able to discriminate between the FQR1 and FQR2 strains because this was present in approximately half of the strains. This region was more commonly found in strains outside of the United States. Another noticeable missing feature in 6 US strains was *CDR20291_1079*, which encodes for a putative teicoplanin resistance protein. Finally, 3 strains were missing a gene cluster corresponding to ethanolamine metabolism. Two of the 3 strains were of the FQR1 lineage and were found to be outliers by maximum-likelihood phylogeny using whole genome SNP analysis. Clinical data were available for these 2 patients, 1 of which had fatal refractory CDI. Coincidentally, these strains were also found to harbor SNPs in several other metabolic pathways that may impact virulence properties ([Supplemental Figure 1B](#sup1){ref-type="supplementary-material"}).

![Gene presence or absence analysis amongst 108 clinical strains. (A) Genes that were covered by sequencing in the R20291 genome for each strain were plotted as green, whereas gene absence is plotted red. Gene absence may have been due to low coverage in some of the strains. A closer view of regions of high variability on the right allows for complete discrimination between FQR1 and FQR2 strains. (B) Antimicrobial resistance genes were found in the genomes of the samples, and (C) overall gene presence is shown for FQR1, FQR2, and the pre-epidemic strains.](ofidis_ofz013_f0002){#F2}

Because the FQR strains are genetically resistant to fluoroquinolones, we also determined whether other known antimicrobial resistance genes were coinherited. In total, 69 of 108 samples (64%) had at least 1 other antimicrobial resistance gene with the most common being *ermB* (67%) encoding the MLSb (macrolide, lincosamide, and streptogramin B) phenotype ([Figure 2B](#F2){ref-type="fig"}). Other genes encoding aminoglycoside (*AAC(6')-Ie-APH(2")-Ia*, *AAC(6')-Im*, *APH2-Ib*, and *Sttr*), β-lactam (*TEM-1d* and *BlaZ*), trimethoprim (*DfrC*), MLSb (*MsrA* and *VgaA*), and tetracycline resistance (*tetM and tetW*) were also present in some strains. Tetracycline resistance was more common in US strains compared with other worldwide strains (n = 17 of 18 total). In general, antimicrobial resistance genes could be used as a means of separating the 2 lineages ([Figure 2B](#F2){ref-type="fig"}). In total, FQR1 strains contained more antimicrobial resistance genes compared with the FQR2 strains ([Figure 2C](#F2){ref-type="fig"}). It is interesting to note that 31.5% of FQR2 strains from Houston were positive for *ermB*, whereas no geographically removed strain was positive for this.

Bayesian phylogenetic and phylogeographic analyses were carried out on the FQR1 and FQR2 strains as previously reported \[[@CIT0005], [@CIT0010]\]. Consistent with these prior findings, our analysis indicated that mutations arose in the *C difficile* ribotype 027 core genome at a rate of 1.4 × 10^−7^ SNPs per site per year corresponding to approximately 1 mutation per genome per year. Bayesian analyses confirmed the distribution of isolates within the fluoroquinolone resistance lineages and also demonstrated sublineages of Houston isolates within FQR1 and FQR2. Emergence of the FQR1 strain was calculated to be as early as 1985, whereas emergence of the FQR2 strain was calculated to be in 1990 ([Figure 3A](#F3){ref-type="fig"}). Ciprofloxacin and norfloxacin were approved shortly before 1985 by the US Food and Drug Administration, suggesting that use of these antibiotics may have contributed to the ribotype 027 epidemic. Although these are predictions for the emergence of the first fluoroquinolone-resistant strains, the strains began proliferating and spreading in the mid-1990s \[[@CIT0005], [@CIT0010]\]. Both lineages are predicted to have emerged from the United States with high probability ([Figure 3B](#F3){ref-type="fig"}). Considering the number of hospital systems in Houston and Texas-wide, we also investigated the transmission events that have occurred within the city and to neighboring cities. Most of the isolates were derived from Texas Medical Center hospitals and were transmitted to other hospitals/sites ([Figure 3C](#F3){ref-type="fig"}). There was significant mixing amongst hospital systems within Houston likely resulting in the unique Houston strains that are described ([Supplemental Figure 3](#sup3){ref-type="supplementary-material"}).

![Bayesian phylogenetic and phylogeographic analyses of FQR1 and FQR2 strains. The computational tool BEAST2 was used to incorporate time and geography variables with the single-nucleotide polymorphism analysis. (A) Phylogenetic analyses are plotted with US Food and Drug Administration approval dates for certain fluoroquinolones. (B) Predictive dissemination of FQR1 (red lines) and FQR2 (blue lines) strains worldwide and (C) within Texas.](ofidis_ofz013_f0003){#F3}

DISCUSSION {#s5}
==========

Prior investigations into the worldwide dissemination of the ribotype 027 epidemic strain are limited by a low number of globally available strains for typing, specifically FQR1 lineage isolates from the United States. Considering this, we sought to conduct a large, epidemiologic study to better understand the emergence of ribotype 027 in the United States. Using whole genome sequencing, we demonstrated that both fluoroquinolone resistance lineages (FQR1 and FQR2) were equally present in hospitalized patients with CDI in Texas. Core genome SNP analysis was able to discriminate between the 2 lineages, as well as determine the presence or absence of specific genes (*Tn6192*, *Tn6105*, *putative teicoplanin resistance gene*, and the *ethanolamine gene cluster*). Worldwide resistance differences were noted including teicoplanin resistance that was relatively absent in US strains. The ethanolamine gene cluster was absent in only 3 strains in our collection, all isolated from the United States. Mechanistic gene mutation studies have shown that absence of this gene cluster increases virulence, suggesting that this may have also contributed to more aggressive infections in humans \[[@CIT0026]\]. Several antimicrobial resistance traits unique to Houston strains were also identified in our collection, including increased presence of tetracycline resistance genes. In general, FQR1 strains had more antimicrobial resistance genes compared with FQR2 strains, which may be partially explained by this strain emerging earlier. All of these findings will need to be expanded and confirmed in future studies.

Although previous reports provided a global overview of the 2 epidemic ribotype 027 lineages, they do not show how isolates differ genetically at the geographic level, especially in the United States. In this study, we demonstrated that sublineages of FQR1 and FQR2 have become unique to the greater Houston vicinity compared with worldwide comparators. This study also provides data to support a hypothesis that extends the potential emergence of the ribotype 027 lineage back to the 1980s and early 1990s. These dates coincide with the clinical use of fluoroquinolone antibiotics in the United States, suggesting that resistance developed quickly after introduction of these drugs into clinical practice \[[@CIT0002]\]. Fluoroquinolone resistance was first documented in *E coli* as early as 1969 after the introduction of nalidixic acid into clinical practice in 1967, and thus resistance in *C difficile* approximately 15 years later may be expected. Compared to the relatively slow mutation rate observed in *C difficile*, *E coli* mutate at a rate almost 10 000 times faster, which likely contributed to the earlier accelerated resistance \[[@CIT0027]\]. However, as fluoroquinolones became more widely used in the 1990s and early 2000s, increased antimicrobial selection pressure on *C difficile* strains increased the likelihood that a fluoroquinolone-resistant mutant could emerge as an epidemic ribotype. This hypothesis will require further testing.

An additional notable finding was that both FQR1 and FQR2 strains were present in equal abundance in the United States, compared with other global sites. FQR1 strains harbored more antimicrobial resistance genes, and 2 FQR1 isolates were identified that predicted more serious infection course. Further studies will be needed to establish whether FQR1 strains remained in the United States because of changes in cellular metabolism (increased SNPs found in metabolic genes) and natural selection due to antibiotic use. This is indicated from the Bayesian genetic analysis ([Figure 3A](#F3){ref-type="fig"}) as a stepwise evolution of the FQR1 strains compared with the FQR2 strains in which sublineages emerged at the same time. Regardless of this, our study shows that these strains are still present in the United States and represent a continued urgent threat.

This study has limitations. We sampled a limited number of regional isolates and compared them to the worldwide collection of ribotype 027 isolates that have already been reported. Increasing sample size would strengthen the Bayesian and phylogeographic analyses and allow more precise mapping of isolates within the United States. In addition, because of the highly international nature of healthcare in the Texas Medical Center Houston, many patients travel to Houston from other countries and may have impacted the phylogeographic analyses. The geographic clustering that we observed in this study will need to be demonstrated in other large regional medical centers as well.

CONCLUSIONS {#s6}
===========

In conclusion, we found that both FQR1 and FQR2 epidemic *C difficile* ribotype 027 lineages were present in our sample cohort and emerged earlier than previous reports coinciding with increased use of fluoroquinolones. Our findings also indicate that local prescribing patterns may have led to antibiotic resistance that is present in these genomes. Looking forward, more epidemiological tracking studies are needed to understand the evolving dynamics of *C difficile*.

Supplementary Data {#s7}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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